Translational Sciences Inc.
Memphis, TN, US· latest recorded location
Translational Sciences Inc. is named on 5 US grants and 7 published applications in this corpus. Its most frequent classification is A61K (Medicines and medical preparations).
- Granted patents
- 5
- Published applications
- 7
- Inventors
- 1
- Granted in 2026 so far
- 0
- Most recent grant
- 31 May 2022
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 1 |
| 2015 | 1 | 0 |
| 2016 | 0 | 1 |
| 2017 | 1 | 0 |
| 2018 | 0 | 1 |
| 2019 | 0 | 0 |
| 2020 | 0 | 1 |
| 2021 | 1 | 0 |
| 2022 | 2 | 2 |
By publication year.
Technology areas
Share of 12 documents
- A61KMedicines and medical preparations12
- C07KPeptides12
- A61PTherapeutic uses of medicines8
- C12QMeasuring or testing processes involving enzymes, nucleic acids or microorganisms4
- G01NInvestigating or analysing materials by determining their chemical or physical properties4
- C12NMicroorganisms or enzymes3
- C12YEnzymes3
Recent patents
- Inhibition of vascular matrix metalloproteinase-9 to treat ischemic injury31 May 2022US 11,345,758 B2
- Serpinf2-binding molecules and method of use thereof1 Feb 2022US 11,236,176 B2
- Prophylaxis of thrombosis3 Aug 2021US 11,078,297 B2
- Method of increasing plasmin activity through antiplasmin conversion5 Dec 2017US 9,834,614 B2
- Method of increasing plasmin activity through antiplasmin conversion6 Oct 2015US 9,150,903 B2
- Serpinf2-Binding Molecules and Method of Use Thereof22 Sep 2022US 2022/0298261 A1
- Inhibition of Vascular Matrix Metalloproteinase-9 to Treat Ischemic Injury22 Sep 2022US 2022/0298262 A1
- Inhibition of Vascular Matrix Metalloproteinase-9 to Treat Ischemic Injury2 Jul 2020US 2020/0207871 A1
- Prophylaxis of Thrombosis13 Dec 2018US 2018/0355058 A1
- Method of increasing plasmin activity through antiplasmin conversion11 Feb 2016US 2016/0039943 A1
Most cited
By later US patents